» Articles » PMID: 32397159

Reconfiguring Nature's Cholesterol Accepting Lipoproteins As Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents

Overview
Date 2020 May 14
PMID 32397159
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Apolipoproteins are critical structural and functional components of lipoproteins, which are large supramolecular assemblies composed predominantly of lipids and proteins, and other biomolecules such as nucleic acids. A signature feature of apolipoproteins is the preponderance of amphipathic α-helical motifs that dictate their ability to make extensive non-covalent inter- or intra-molecular helix-helix interactions in lipid-free states or helix-lipid interactions with hydrophobic biomolecules in lipid-associated states. This review focuses on the latter ability of apolipoproteins, which has been capitalized on to reconstitute synthetic nanoscale binary/ternary lipoprotein complexes composed of apolipoproteins/peptides and lipids that mimic native high-density lipoproteins (HDLs) with the goal to transport drugs. It traces the historical development of our understanding of these nanostructures and how the cholesterol accepting property of HDL has been reconfigured to develop them as drug-loading platforms. The review provides the structural perspective of these platforms with different types of apolipoproteins and an overview of their synthesis. It also examines the cargo that have been loaded into the core for therapeutic and imaging purposes. Finally, it lays out the merits and challenges associated with apolipoprotein-based nanostructures with a future perspective calling for a need to develop "zip-code"-based delivery for therapeutic and diagnostic applications.

Citing Articles

Apolipoprotein E3 Containing Nanodiscs as Vehicles for Transport and Targeted Delivery of Flavonoid Luteolin.

Benedicto V, Haguar Z, Abdulhasan A, Narayanaswami V ACS Omega. 2024; 9(2):2988-2999.

PMID: 38250386 PMC: 10795050. DOI: 10.1021/acsomega.3c09120.


Enhancement of Antioxidant and Anti-Glycation Properties of Beeswax Alcohol in Reconstituted High-Density Lipoprotein: Safeguarding against Carboxymethyllysine Toxicity in Zebrafish.

Cho K, Baek S, Nam H, Bahuguna A Antioxidants (Basel). 2023; 12(12).

PMID: 38136235 PMC: 10740997. DOI: 10.3390/antiox12122116.


Isolation of recombinant apolipoprotein E4 N-terminal domain by foam fractionation.

Lethcoe K, Fox C, Hafiane A, Kiss R, Ryan R Protein Expr Purif. 2023; 210:106319.

PMID: 37290717 PMC: 10330888. DOI: 10.1016/j.pep.2023.106319.


Lipoprotein Particles as Shuttles for Hydrophilic Cargo.

Weber F, Axmann M, Horner A, Schwarzinger B, Weghuber J, Plochberger B Membranes (Basel). 2023; 13(5).

PMID: 37233532 PMC: 10222575. DOI: 10.3390/membranes13050471.


Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications.

Aranda-Lara L, Isaac-Olive K, Ocampo-Garcia B, Ferro-Flores G, Gonzalez-Romero C, Mercado-Lopez A Molecules. 2022; 27(20).

PMID: 36296638 PMC: 9610567. DOI: 10.3390/molecules27207046.


References
1.
Simonsen J . Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications. Nanomedicine. 2016; 12(7):2161-2179. DOI: 10.1016/j.nano.2016.05.009. View

2.
Kuai R, Subramanian C, White P, Timmermann B, Moon J, Cohen M . Synthetic high-density lipoprotein nanodisks for targeted withalongolide delivery to adrenocortical carcinoma. Int J Nanomedicine. 2017; 12:6581-6594. PMC: 5593402. DOI: 10.2147/IJN.S140591. View

3.
Park K . Transport across the blood-brain barrier using albumin nanoparticles. J Control Release. 2009; 137(1):1. DOI: 10.1016/j.jconrel.2009.05.004. View

4.
Chu A, Tsang S, Lo E, Fung K . Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 2002; 70(5):591-601. DOI: 10.1016/s0024-3205(01)01441-2. View

5.
Huntosova V, Buzova D, Petrovajova D, Kasak P, Nadova Z, Jancura D . Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells. Int J Pharm. 2012; 436(1-2):463-71. DOI: 10.1016/j.ijpharm.2012.07.005. View